By Josh Beckerman


Merck & Co.'s Recarbrio received U.S. Food and Drug Administration approval to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Recarbrio, a combination of imipenem-cilastatin and relebactam, was previously approved to treat certain patients with complicated urinary tract infections and complicated intra-abdominal infections.

The FDA said the application was granted a Qualified Infectious Disease Program designation.


Write to Josh Beckerman at


(END) Dow Jones Newswires

June 04, 2020 17:48 ET (21:48 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.